Efficacy and safety of etelcalcetide compared with cinacalcet in patients received hemodialysis with secondary hyperparathyroidism. Results from a prospective randomized trial
- Авторлар: Shutov E.V.1,2, Kotlyarova G.V.1, Lysenko K.M.1, Ryabinskaya G.V.1, Lashutin S.V.1, Markelova I.A.1, Rubleva S.Y.1
-
Мекемелер:
- Botkin Clinical City Hospital
- Russian Medical Academy of Continuous Professional Education
- Шығарылым: Том 13, № 2 (2021)
- Беттер: 34-40
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273760
- DOI: https://doi.org/10.18565/nephrology.2021.2.34-40
- ID: 273760
Дәйексөз келтіру
Аннотация
Негізгі сөздер
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
Evgeny Shutov
Botkin Clinical City Hospital; Russian Medical Academy of Continuous Professional EducationDr. Sci. (Med.), Professor, Head of the Interdistrict Nephrological Center; Head of the Department of Nephrology and Hemodialysis Moscow, Russia; Moscow, Russia
Galina Kotlyarova
Botkin Clinical City HospitalCand. Sci. (Med.), Head of the Dialysis Department Moscow, Russia
Ksenia Lysenko
Botkin Clinical City HospitalNephrologist Moscow, Russia
Galina Ryabinskaya
Botkin Clinical City HospitalCand. Sci. (Med.), Doctor-Laboratory Assistant Moscow, Russia
Sergey Lashutin
Botkin Clinical City HospitalCand. Sci .(Med.), Nephrologist Moscow, Russia
Irina Markelova
Botkin Clinical City HospitalNephrologist Moscow, Russia
Svetlana Rubleva
Botkin Clinical City HospitalNephrologist Moscow, Russia
Әдебиет тізімі
- Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol 2004;15:2208-18.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Working Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;113(Suppl.):S1-130.
- Wesseling-Perry K, Pereira R.C., Tseng C.H., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2012;7:146-52.
- Drueke T.B., Massy Z.A. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016;89:289-302.
- Graciolli F.G., Neves K.R., Barreto F., et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91:1436-46.
- Barker S.L., Pastor J., Carranza D., et al. The demonstration of alphaKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30:223-33.
- Nakatani T., Sarraj B., Ohnishi M., et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) - mediated regulation of systemic phosphate homeostasis. FASEB J.: official publication of the Federation of American Societies for Experimental Biology. 2009;23:433-41.
- Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2011;6:913-21.
- Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004;350:1516-25.
- Goldsmith D., Covic A., Vervloet M., et al. Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; Chronic Kidney Disease-Mineral Bone Disease CKD-MBD working group and the European Renal Best Practice ERBP advisory board. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol. Dial. Transplant. 2015;30:698-700.
- Ketteler M., Block G.A., Evenepoel P., et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017;92:26- 36. Erratum in: Kidney Int. 2017;92:1558.
- Custodio M.R., Canziani M.E., Moyses R.M., et al. [Clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease]. J. Bras. Nefrol. 2013;35:308-22. Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor,for the treatment of secondary hyperparathyroidism in hemodialysis patients. J. Pharmacol. Exp. Ther. 2013;346(2):229-40.
- Block G.A., Bushinsky D.A., Cheng S., et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA. 2017;317(2):156-64.
- Block G.A., Bushinsky D.A., Cunningham J., et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017; 317(2): 146-155.
- Martin K.J., Pickthorn K., Huang S., et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191-7.
- KDIGO Workgroup. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) 2017 [cited 2018 January 31]. Available from: http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf.
- Akira Mima, Kosuke Tansho, Dai Nagahara, Kenji Watase Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study. J. Int. Med. Res. 2018;46(11):4578-85.
- Palmer S.C., Mavridis D., Johnson D.W., et al. Comparative Effectiveness of Calcimimetic Agentsfor Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am. J. Kidney Dis. 2020;76(3):321-30.
- Block G.A., Bushinsky D.A., Cheng S., et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017;317(2):156-64.
- Regidor D.L., Kovesdy C.P., Mehrotra R., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J. Am. Soc. Nephrol. 2008;19:2193-203.
- Beddhu S., Ma X., Baird B., et al. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009;4:1805-10.
- Blayney M.J., Pisoni R.L., Bragg-Gresham J.L., et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74(5):655-63. doi: 10.1038/ki.2008.248.
- Yamashita T., Shizuku J., Ohba T., et al. Serum alkaline phosphatase levels and mortality of chronic hemodialysis patients. Int. J. Clin. Med. 2011;2:388-93.
- Shantouf R., Kovesdy C.P, Kim Y., et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009;4:1106-14.
- Beige J., Wendt R., Girndt M., et al. Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. BMJ. Open. 2014;4(2):e004275.
- Yu Fan, Xin Jin, Menglin Jiang, et al. Elevated serum alkaline phosphatase and cardiovascular or all-cause mortality risk in dialysis patients: A meta-analysis Sci. Rep. 2017;7:13224.
- Moester M.J., Papapoulos S.E., Lowik C.W., et al. Sclerostin: Current knowledge and future perspectives. Calcif. Tissue Int. 2010;87:99-107.
- Khosla S., Westendorf J.J., Oursler M.J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 2008;118:421-8.
- Sato M., Hanafusa N., Kawaguchi H., et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press. R. 2018;43:1023-33.
- Nowak A., Artunc F, Serra A.L., Pollock E., et al. Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients? Kidney Blood Press R. 2015;40:266-76. doi: 10.1159/000368502.
- Delanaye P., Krzesinski J.M., Warling X., et al. Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients. Nephron Clin. Pract. 2014;128:127-34.
- Drechsler C., Evenepoel P., Vervloet M.G., et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: Results from the NECOSAD study. Nephrol. Dial. Transpl. 2015;30:288-93.
- Jean G., Chazot C., Bresson E., Zaoui E., Cavalier E. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Nephron. 2016;132:181-90.
- Wang X.R., Yuan L.A., Zhang J.J., et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrol. 2017;22:286-92.
- Goncalves F.L.C., Elias R.M., dos Reis L.M., et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC. Nephrol. 2014;15:190. doi: 10.1186/1471-2369-15-190.
- Persy V., D’Haese P. Vascular calcification and bone disease: The calcification paradox. Trends Mol. Med. 2009;15:405-16.
- De Mare A., Maudsley S., Azmi A., et al. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis. Toxins. 2019;11:428.
- Viaene L., Behets G.J., Claes K., et al. Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis? Nephrol. Dial. Transpl. 2013;28:3024-30.
- Bisson S.K., Ung R.V., Picard S., et al. High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats. J. Bone Miner. Metab. 2019;37:212-23.
- Saag K.G., Petersen J., Brandi M.L., et al. Romosozumab or Alendronate for Fracture Prevent ion in Women with Osteoporosis. N. Engl. J. Med. 2017;377(15):1417-27.
- Isakova T., Wahl P., Vargas G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-8.
- Poelzl G., Trenkler C., Kliebhan J., et al. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur. J. Clin. Invest. 2014;44(12):1150-8.
- Wolf M., Block G.A., Chertow G.M., et al. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin. Kidney J. 2020;13(1):75-84.
- Sawires H.K., Essam R.M., Morgan M.F., et al. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease. Nephron. 2015;129(4):293-9.
- Komaba H., Koizumi M., Tanaka H., et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2012;27(5):1967-9.
Қосымша файлдар
![](/img/style/loading.gif)